Since, the discovery of the cannabinoid receptor 1 (CB1R) system, and the subsequent disclosure of its critical roles in the developing and progression of obesity, the pursuit for effective CB1R antagonists to manage morbid obesity haven’t lost its momentum (Sharma et al., 2014; Murineddu et al., 2017). This evidence concerns the gene CNR1 and obesity disorder.